Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.85 |
| ▸ | ROCK1 | Q13464 | 16/20 | 0.85 |
| ▸ | RPS6KA1 | Q15418 | 15/20 | 0.85 |
| ▸ | AKT2 | P31751 | 14/20 | 0.85 |
| ▸ | RPS6KA5 | O75582 | 7/20 | 0.85 |
| ▸ | AKT3 | Q9Y243 | 7/20 | 0.83 |
| ▸ | GSK3B | P49841 | 4/20 | 0.83 |
| ▸ | CIT | O14578 | 1/20 | 0.83 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.83 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.83 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.83 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.83 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.83 |
| ▸ | ULK1 | O75385 | 1/20 | 0.83 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.83 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.83 |
| ▸ | SMC2 | O95347 | 1/20 | 0.83 |
| ▸ | LATS1 | O95835 | 1/20 | 0.83 |
| ▸ | PAK4 | O96013 | 1/20 | 0.83 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487696 | 0.92 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Gsk-690693 SCHEMBL29387832 | 0.91 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Gsk-690693 SCHEMBL2195376 | 0.91 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Gsk-690693 SCHEMBL310452 | 0.91 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL22827777 | 0.89 | AKT1 (0.81) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL10053680 | 0.89 | AKT1 (0.91) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Hydrochloric Acid SCHEMBL690160 | 0.88 | AKT1 (0.90) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL15446768 | 0.87 | AKT1 (0.83) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL13435151 | 0.86 | AKT1 (0.74) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3488371 | 0.86 | AKT1 (0.74) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | AKT1 1730/4885ROCK1 3172/4885RPS6KA1 1506/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | AKT1 1356/4885ROCK1 2414/4885RPS6KA1 536/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | AKT1 1356/4885ROCK1 2414/4885RPS6KA1 536/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | AKT1 1730/4885ROCK1 3172/4885RPS6KA1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.